Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02728661
Other study ID # K12HS023011
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date May 2016
Est. completion date June 2017

Study information

Verified date October 2023
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PACE is a patient-centered weight loss program that was developed specifically for knee replacements based on input from stakeholders, including knee replacement patients, physical therapists, and orthopedic surgeons. In this pilot study, participants undergoing knee replacement will be randomized to either start a weight loss program before surgery (PACE) or after surgery (Delayed PACE). Both programs will receive a 14-week intervention and complete assessments at baseline (up to 6 weeks prior to surgery), 12 weeks after surgery, and 26 weeks after surgery.


Description:

It is estimated that half of patients diagnosed with knee osteoarthritis (OA) will need a total knee replacement (TKR) during their lifetime. Of patients who need a TKR, 80-95% are overweight or obese. While patients are encouraged to lose weight, limited, if any, guidance is provided to achieve recommended weight loss. Many patients perceive that TKR is a necessary precursor for the initiation of weight loss. Yet, 66% of patients actually gain weight by 2 years after surgery. Patients undergoing TKR not only face unique barriers (i.e., pain, mobility limitations, motivation) to weight loss, but also have to balance pre- and post-operative concerns from physicians, surgeons, and rehabilitation specialists. To best accommodate the needs of both patients (pre- and post-TKR) and healthcare professionals (i.e., surgeon, physical therapist), patient and stakeholder engagement and activation is imperative in the development of a patient-centered weight loss intervention. Investigators completed 20 interviews with patients pre- and post-TKR and identified weight loss barriers, preferred intervention components (e.g., delivery method, contact frequency, self-monitoring modality) and patient-reported outcomes (e.g., physical function, pain) viewed as critical by patients. Investigators developed a patient-centered weight loss program (PACE) guided by these results and additional input from stakeholders to meet the needs of patients and healthcare professionals. PACE is a randomized pilot study comparing weight loss and patient-reported outcomes between PACE (program starting up to 6 weeks pre-TKR to 12 weeks post-TKR) and Delayed PACE (program starting 12 weeks post-TKR to 26 weeks post-TKR).


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 40 Years to 79 Years
Eligibility Inclusion Criteria: - BMI between 25-45 kg/m2 - Have a scheduled knee replacement at least 1 week away from baseline assessment - Obtain physician approval to participate - English speaking - willing to attend 3 in-person assessments. Exclusion Criteria: - Have any contraindications to diet or weight loss - Undergoing simultaneous bilateral knee replacement or have a scheduled or anticipated knee replacement for the contralateral knee in the next 26 weeks - Have a mobility limiting comorbidity besides relating to TKR - Taking anti-obesity medications - Enrolled in a formal weight loss program - Have had or is planning to have bariatric/gastric/lapband surgery - Is planning to relocate out of the Chicago land area in the next 12 months.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
PACE
PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
Delayed PACE
Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.

Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University Agency for Healthcare Research and Quality (AHRQ)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in physical activity objectively-measured with accelerometry Change from baseline to 12 and 26 weeks
Other Behavioral adherence assessed by session and self-monitoring completion 26 weeks post-op
Primary Change in weight measured with a balance-beam scale Change from baseline to 12 and 26 weeks
Secondary Change in physical function assessed by the timed up and go Change from baseline to 12 and 26 weeks
Secondary Change in pain measured by WOMAC Change from baseline to 12 and 26 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04080401 - Effectiveness of a Novel Gaming System on Post-operative Rehabilitation Outcomes After Total Knee Arthroplasty N/A
Completed NCT02648958 - Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations N/A
Completed NCT00846807 - Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery N/A
Completed NCT04372173 - An Evaluation of Clotting Factor Activity Before and After Total Hip Arthroplasty
Recruiting NCT01909375 - American Joint Replacement Registry
Terminated NCT01153698 - Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
Completed NCT01184989 - Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate Phase 4
Active, not recruiting NCT00114036 - Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE) N/A
Completed NCT03407885 - The Impact of Medicare Bundled Payments N/A
Completed NCT01857349 - Efficacy of Surgical Preparation Solutions in Knee Surgery N/A
Completed NCT00847301 - Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery N/A
Recruiting NCT04697004 - SMR Stemless Reverse vs SMR Reverse Shoulder System N/A
Completed NCT03158623 - Wound Additives in Primary Total Joint Athroplasty Phase 3

External Links